No Data
No Data
Junshi Bio: From a laboratory of less than 300 square meters in 2012 to a leading innovative drug | Zhangjiang's new productive forces
Currently, junshi bio has four innovative drugs, including Teripriline and Adamonab, which have achieved commercial sales. Zhang Zhuobing believes that the research and development of innovative drugs is endless, just like innovation itself. in order for the innovative drug industry to achieve long-term development, it needs to establish an effective system for the transformation of scientific research achievements, which directly affects the industrialization efficiency of biotech enterprises.
junshi bio (688180.SH): has repurchased 0.8159 million shares, and the repurchase plan has been completed.
On September 9th, Junshi Bio (688180.SH) announced that as of the disclosure date of this announcement, the company's share repurchase plan has been completed. The company repurchased a total of 0.8159 million shares through the Shanghai Stock Exchange trading system using centralized bidding trade, accounting for 0.0828% of the total share capital. The highest repurchase price was RMB 41.69 per share, and the lowest price was RMB 29.03 per share. The average repurchase price was RMB 37.85 per share, with a total fund payment of RMB 30,883,207.73 (excluding stamp duty, transaction commission and other fees).
Junshi Biosciences (688180.SH): Has repurchased 0.0828% of the shares.
On September 2, junshi bio (688180.SH) announced that as of August 31, 2024, the company has repurchased a total of 815,871 shares through the trading system of the Shanghai Stock Exchange by centralized bidding trading, accounting for 0.0828% of the total share capital of the company. The highest repurchase price was RMB 41.69 per share, and the lowest price was RMB 29.03 per share. The total amount paid was RMB 30,883,207.73 (excluding stamp duty, transaction commissions, and other trading fees).
Shanghai Junshi Biosciences' Losses Shrink 35% in H1 as Revenue Jumps 17%
Express News | Junshi Biosciences Announces 2024 Interim Financial Results and Provides Corporate Updates
Junshi Biotech 2024 Semi-Annual Report
No Data
No Data